[A patient with Crow-Fukase syndrome associated with pulmonary plasmacytoma].
We here reported a 54-year-old female patient with Crow-Fukase syndrome associated with pulmonary plasmacytoma. She was found to have scattered tumor in 1990. Although the tumor had slowly grown for the last 10 years, she showed no clinical symptoms. Numbness and weakness of lower extremities began in June 1999, and she was referred to Kyoto University Hospital on Oct. 21 1999 for evaluation of progressive symptoms. She had skin pigmentation, edema of the lower extremities, lymphadenopathy, muscle weakness and sensory disturbance in a glove-and-stocking distribution. Serological examination showed monoclonal IgG-lambda gammopathy. Serum vascular endothelial growth factor (VEGF) was markedly elevated. Microscopic studies on biopsied sural nerve demonstrated mild decrease of myelinated fibers. Immunohistochemically, the pulmonary tumor was defined as an IgG (lambda type) plasmacytoma. After treatment with melphalan-prednisolone therapy, the neurological symptoms improved along with decrease of serum VEGF levels as well as the size of pulmonary plasmacytoma. This is the first report of a patient with Crow-Fukase syndrome associated with pulmonary plasmacytoma. This case suggests that growth of pulmonary plasmacytoma might have played an important role in the overproduction of VEGF and thus development of Crow-Fukase syndrome.
Shinde
A
A
Department of Neurology, Kyoto University Graduate School of Medicine.
Matsumae
H
H
Maruyama
A
A
Oida
J
J
Kawamoto
Y
Y
Kouhara
N
N
Oka
N
N
Shirase
T
T
Kitaichi
M
M
Akiguchi
I
I
Shibasaki
H
H
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications* / Q000188:drug therapy; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D016878:POEMS Syndrome / Q000188:drug therapy / Q000209:etiology*; D010954:Plasmacytoma / Q000150:complications* / Q000188:drug therapy; D011239:Prednisolone / Q000008:administration & dosage
D018906:Antineoplastic Agents, Alkylating; D011239:Prednisolone; D008558:Melphalan